Therapeutic targeting of miRNAs in neuroblastoma

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 9, 2010, Pages 951-962

  Stallings, Raymond L ^a,b   Foley, Niamh H ^a,b   Bryan, Kenneth ^a,b   Buckley, Patrick G ^a,b   Bray, Isabella ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

AKT; ATRA; Chromosomal imbalance; Differentiation; MicroRNA; MiR 184; MiR 34a; MYCN; Neuroblastoma

Indexed keywords

ANTAGOMIR 17 5P; ANTINEOPLASTIC AGENT; GANGLIOSIDE ANTIBODY; MICRORNA; MICRORNA 184; MICRORNA 26A; MICRORNA 34A; MICRORNA 34C; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; DRUG TARGETING; HUMAN; LIVER CELL CARCINOMA; METASTASIS; NEUROBLASTOMA; NONHUMAN; PROGNOSIS; REVIEW;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEUROBLASTOMA;

EID: 77955442058     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.510136     Document Type: Review

References (76)

1. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-531 (Pubitemid 38868508)
2. Duursma AM, Kedde M, Schrier M, et al. miR-148 targets human DNMT3b protein coding region. RNA 2008;14:872-877 (Pubitemid 351574909)
3. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008;30:460-471
4. Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature 2008;455:64-71
5. Gu S, Jin L, Zhang F, et al. Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol 2009;16:144-150
6. Place RF, Li LC, Pookot D, et al. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 2008;105:1608-1613 (Pubitemid 351346562)
7. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-1934
8. Kim VN. Small RNAs: classification, biogenesis, and function. Mol Cells 2005;19:1-15
9. Breving K, Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 2010;42:1316-1329
10. Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 2004;5(9):R68
11. Blenkiron C, Miska EA. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum Mol Genet 2007;16(Spec No 1):R106-13 (Pubitemid 47241849)
12. Calin GA. MicroRNAs and cancer: what we know and what we still have to learn. Genome Med 2009;1(8):78
13. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007;6:2127-2132 (Pubitemid 47450412)
14. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007;67:11099-11101 (Pubitemid 350248530)
15. Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009;15:456-462
16. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007;43:1529-1544
17. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216 (Pubitemid 37328872)
18. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009;107:46-57
19. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-2253
20. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124 (Pubitemid 14106392)
21. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 2003;9:52-58 (Pubitemid 36109715)
22. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-2299 (Pubitemid 46218721)
23. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-1033
24. Stallings RL. Are chromosomal imbalances important in cancer? Trends Genet 2007;23:278-283
25. Brinkschmidt C, Christiansen H, Terpe HJ, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 2001;36:11-13
26. Plantaz D, Vandesompele J, Van Roy N, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 2001;91:680-686 (Pubitemid 32115264)
27. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67:976-983 (Pubitemid 46270752)
28. Schulte JH, Horn S, Otto T, et al. MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer 2008;122:699-704 (Pubitemid 350308967)
29. Bray I, Bryan K, Prenter S, et al. Widespread dysregulation of miRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009;4(11):e7850
30. Mestdagh P, Fredlund E, Pattyn F, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010;29:1394-1404
31. Schulte JH, Schowe B, Mestdagh P, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010: published online 5 May 2010, doi: 10.1002/ijc.25436
32. Murphy DM, Buckley PG, Bryan K, et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-Box motifs and regions of DNA hypermethylation. PLoS One 2009;4(12):e8154
33. Afanasyeva EA, Hotz-Wagenblatt A, Glatting KH, Westermann F. New miRNAs cloned from neuroblastoma. BMC Genomics 2008;9:52 (Pubitemid 351314944)
34. Schulte JH, Marschall T, Martin M, et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010: published online 13 May 2010, doi:10.1093/nar/gkq342
35. Buckley PG, Alcock L, Bryan K, et al. Chromosomal and miRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. Clin Cancer Res 2010;16:2971-2978
36. Mestdagh P, Fredlund E, Pattyn F, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010;29:1394-1404
37. Fischer M, Bauer T, Oberthur A, et al. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010;29:865-875
38. Vermeulen J, De Preter K, Naranjo A, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10:663-671
39. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-5078 (Pubitemid 46631411)
40. Cole KA, Attiyeh EF, Mosse YP, et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008;6:735-742
41. Foley NH, Bray IM, Tivnan A, et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 2010;9:83
42. Wei JS, Song YK, Durinck S, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008;27:5204-5213
43. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007;26:5017-5022 (Pubitemid 47172643)
44. Bommer GT, Gerin I, Feng Y, et al. p53-Mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-1307 (Pubitemid 47176893)
45. Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008;582:1564-1568
46. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-752
47. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-1134 (Pubitemid 47014436)
48. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-743 (Pubitemid 46856247)
49. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-1593 (Pubitemid 47327945)
50. Corney DC, Flesken-Nikitin A, Godwin AK, et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007;67:8433-8438 (Pubitemid 47437414)
51. Hosoi G, Hara J, Okamura T, et al. Low frequency of the p53 gene mutations in neuroblastoma. Cancer 1994;73:3087-3093 (Pubitemid 24170786)
52. Fontana L, Fiori ME, Albini S, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 2008;3(5):e2236
53. Wei JS, Johansson P, Chen QR, et al. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009;15:5560-5568
54. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833 (Pubitemid 40839734)
55. Chayka O, Corvetta D, Dews M, et al. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst 2009;101:663-677
56. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2699-2708 (Pubitemid 33049455)
57. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15:867-910
58. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-406 (Pubitemid 15198727)
59. Laneve P, Di Marcotullio L, Gioia U, et al. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA 2007;104:7957-7962 (Pubitemid 47185858)
60. Thiele CJ, Israel MA. Regulation of N-myc expression is a critical event controlling the ability of human neuroblasts to differentiate. Exp Cell Biol 1988;56:321-333
61. Le MT, Xie H, Zhou B, et al. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol 2009;29:5290-5305
62. Evangelisti C, Florian MC, Massimi I, et al. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J 2009;23:4276-4287
63. Chen H, Shalom-Feuerstein R, Riley J, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun 394:921-927
64. Beveridge NJ, Tooney PA, Carroll AP, et al. Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal 2009;21:1837-1845
65. Loven J, Zinin N, Wahlstrom T, et al. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci USA 107:1553-1558
66. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12:247-256
67. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-1065 (Pubitemid 44325933)
68. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009;69:6275-6281
69. Guo J, Dong Q, Fang Z, et al. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol Ther 2010;9:446-452
70. Calin GA, Liu CG, Ferracin M, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007;12:215-229 (Pubitemid 47333418)
71. Scaruffi P, Stigliani S, Moretti S, et al. Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 2009;9:441
72. Mestdagh P, Fredlund E, Pattyn F, et al. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene 2010;29:3583-3592
73. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-1017
74. Zhang S, Chen L, Jung EJ, Calin GA. Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther 2010;87:754-758
75. Li C, Feng Y, Coukos G, Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J 2009;11:747-757
76. Li Z, Thiele CJ. Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway. Expert Opin Ther Targets 2007;11:1611-1621 (Pubitemid 350300963)